Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049530 · ClinicalTrials.gov registry record · Phase 2
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00049530 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 32 participants.
The verdict
NCT00049530, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
RATIONALE: Peginterferon (PEG-interferon) alfa-2b may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of PEG-interferon alfa-2b in treating patients who have stage IV melanoma.
Interventions
- BIOLOGICAL PEG-interferon alfa-2b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2004-01-13 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00049530
The ClinicalTrials.gov registry entry for NCT00049530 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PEG-interferon alfa-2b is the first listed.
NCT00049530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00049530 about?
NCT00049530 is a clinical study titled "PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma". RATIONALE: Peginterferon (PEG-interferon) alfa-2b may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of PEG-interferon alfa-2b in treating patients who have stage IV melanoma.
What is the current status of trial NCT00049530?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2004-01-13. Estimated completion is 2014-06.
What interventions are being tested in trial NCT00049530?
The interventions under investigation include: PEG-interferon alfa-2b (BIOLOGICAL).
Who is sponsoring clinical trial NCT00049530?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.